CHRAC1 and ovarian carcinoma: In ovarian cancer, YY1 induces the transcription of PART1, enhances resistance to cisplatin, and inhibits apoptosis by modulating the miR-512-3p/chromatin accessibility complex subunit 1 (CHRAC1) axis [59].